COMy 2019 | Managing CRS after anti-BCMA CAR-T for myeloma
He Huang, MD, PhD, of Zhejiang University School of Medicine, Zhejiang, China discusses how the majority of patients receiving BCMA CAR-T therapies suffer from cytokine release syndrome (CRS). Dr Huang also discusses different treatments including the anti-interleukin-6 antibodies. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.
Get great new content delivered to your inboxSign up